A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT

A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1

Published:2020-08-19 Issue:5 Volume:38 Page:792-798
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Heibl Sonja¹,Buxhofer‐Ausch Veronika²³,Schmidt Stefan⁴,Webersinke Gerald⁵,Lion Thomas⁶,Piringer Gudrun¹,Kuehr Thomas¹,Wolf Dominik⁴,Melchardt Thomas⁷⁸,Greil Richard⁷⁸,Thaler Josef¹

Affiliation:

1. Department of Internal Medicine IV Klinikum Wels‐Grieskirchen Wels Austria

2. Department of Internal Medicine I with Hematology Stem Cell Transplantation Hemostaseology and Medical Oncology Ordensklinikum Linz GmbH Elisabethinen Linz Austria

3. Medical Faculty Johannes Kepler University Linz Linz Austria

4. Department of Internal Medicine V (Hematology and Oncology) Innsbruck Medical University Innsbruck Austria

5. Labor für Molekulargenetische Diagnostik Ordensklinikum Linz GmbH Barmherzige Schwestern Linz Austria

6. Labdia Labordiagnostik GmbH Children's Cancer Research Institute Vienna Austria

7. Department of Internal Medicine III with Haematology Medical Oncology Haemostaseology Infectiology and Rheumatology Oncologic Center Paracelsus Medical University Salzburg Austria

8. Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials (SCRI‐CCCIT) Cancer Cluster Salzburg Salzburg Austria

Funder

AOP Orphan Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2786

Reference23 articles.

1. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

2. Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products